378 related articles for article (PubMed ID: 18465327)
1. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
4. Loss of antigenicity in stored sections of breast cancer tissue microarrays.
Fergenbaum JH; Garcia-Closas M; Hewitt SM; Lissowska J; Sakoda LC; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):667-72. PubMed ID: 15066936
[TBL] [Abstract][Full Text] [Related]
5. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma.
Sebastiani V; Botti C; Di Tondo U; Visca P; Pizzuti L; Santeusanio G; Alo PL
Anticancer Res; 2006; 26(4B):2983-7. PubMed ID: 16886624
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
Oyaizu T; Arita S; Hatano T; Tsubura A
J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
[TBL] [Abstract][Full Text] [Related]
8. Validation of tissue microarray technology in malignant peripheral nerve sheath tumours.
Cunha KS; Caruso AC; Gonçalves AS; Bernardo VG; Pires AR; da Fonseca EC; de Faria PA; da Silva LE; Geller M; de Moura-Neto RS; Lopes VS
J Clin Pathol; 2009 Jul; 62(7):629-33. PubMed ID: 19318344
[TBL] [Abstract][Full Text] [Related]
9. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
J Clin Pathol; 2007 Apr; 60(4):397-404. PubMed ID: 16775123
[TBL] [Abstract][Full Text] [Related]
10. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
11. Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications.
Talman ML; Rasmussen BB; Andersen J; Christensen IJ
Acta Oncol; 2008; 47(4):789-94. PubMed ID: 18465350
[TBL] [Abstract][Full Text] [Related]
12. Tissue microarrays for rapid linking of molecular changes to clinical endpoints.
Torhorst J; Bucher C; Kononen J; Haas P; Zuber M; Köchli OR; Mross F; Dieterich H; Moch H; Mihatsch M; Kallioniemi OP; Sauter G
Am J Pathol; 2001 Dec; 159(6):2249-56. PubMed ID: 11733374
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG
Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083
[TBL] [Abstract][Full Text] [Related]
15. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
[TBL] [Abstract][Full Text] [Related]
16. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions.
Goussia A; Agnantis NJ; Athanassiadou S; Stefanou D
Anticancer Res; 1995; 15(5B):2313-8. PubMed ID: 8572645
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
[TBL] [Abstract][Full Text] [Related]
19. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
Mann GB; Fahey VD; Feleppa F; Buchanan MR
J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
